Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Sep 2014
Randomized Controlled Trial Controlled Clinical TrialPatients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens.
Health utilities measure patients' preferences for a health state. ⋯ Patients' health utilities are minimally impacted by sofosbuvir + ribavirin treatment, as compared to interferon-based, therapy regardless of treatment duration. Clinical trials' numbers: NCT01542788 (POSITRON), NCT01497366 (FISSION), NCT01604850 (FUSION), NCT01641640 (NEUTRINO).
-
Aliment. Pharmacol. Ther. · Aug 2014
Small intestinal permeability is increased in diarrhoea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders.
Intestinal permeability has been studied in small groups of IBS patients with contrasting findings. ⋯ Small intestinal permeability is increased in patients with IBS-D compared to healthy controls, irrespective of confounding factors. Adjustment for confounders is necessary when studying intestinal permeability, especially in a heterogeneous disorder such as IBS.
-
Aliment. Pharmacol. Ther. · Aug 2014
Clinical TrialEfficacy of the neurokinin-1 receptor antagonist aprepitant in children with cyclical vomiting syndrome.
Aprepitant (Emend, Merck Sharp & Dohme Ltd, Haarlem, the Netherlands), a neurokinin-1 receptor antagonist, prevents vomiting in a range of conditions. No data are available on its use in children with cyclical vomiting syndrome (CVS). ⋯ Aprepitant appears effective for both acute and prophylactic management of paediatric cyclical vomiting syndrome refractory to conventional therapies.
-
Aliment. Pharmacol. Ther. · Aug 2014
Mortality after total colectomy in 3084 patients with inflammatory bowel disease: a population-based cohort study.
A high post-operative mortality has been reported following colectomy in patients with inflammatory bowel disease (IBD), especially in some patient groups. ⋯ The 40-day mortality following total colectomy in IBD patients in Sweden is low, except in patients ≥59 years old.